Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

Yan, Tristan D.; Deraco, Marcello; Baratti, Dario; Kusamura, Shigeki; Élias, Dominique; Gléhen, Olivier; Gilly, François Noël; Levine, Edward A.; Shen, Perry; Mohamed, Faheez; Moran, Brendan; Morris, David L.; Chua, Terence C.; Piso, Pompiliu; Sugarbaker, Paul H.

doi:10.1200/jco.2009.23.9640

Cited by 615 publications

(462 citation statements)

References 29 publications

Supporting

Mentioning

429

Contrasting

Unclassified

Order By: Relevance

“…This is encouraged by promising treatment outcomes published by several specialist centers worldwide. [1][2][3][4][5] As DMPM evolves into a surgically treatable disease, a globally accepted staging system is needed to allow meaningful comparisons and evaluations.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5] However, there are problems with using CC score for staging DMPM, as this prognostic information is unavailable preoperatively in the patient selection process. In an attempt to predict the likelihood of achieving complete cytoreduction, Yan et al published a radiologic staging system for DMPM showing that interpretive CT findings of the small bowel and mesentery are useful in determining operability of a patient with DMPM.…”

Section: Completeness Of Cytoreductionmentioning

confidence: 99%

“…[1][2][3][4][5] With this multimodality treatment approach, complete macroscopic cytoreduction is performed. Importantly, this allows adequate tumor specimens to be analyzed.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*

Yan

Deraco²,

Élias

et al. 2010

Cancer

Self Cite

135

View full text Add to dashboard Cite

A novel digital active homodyne demodulation scheme to eliminate the signal fading in interferometric fiber‐optic sensors is proposed. The error signal is obtained by the square‐wave phase modulation and then the digital correlation detection technique is applied to demodulate the low‐frequency environmental phase drift and generate the offset phase, which is then fed back the integrated optical phase modulator to lock the interferometer in quadrature. The high‐frequency signal phase can be read out and recovered from the photodetector output with the interferometer in quadrature. The simulation and experimental results verify the feasibility of the proposed scheme, which obviates the feedback integrator saturation and the system resetting problem encountered in the conventional active homodyne detection schemes. © 2010 Wiley Periodicals, Inc. Microwave Opt Technol Lett 53:20–23, 2011; View this article online at wileyonlinelibrary.com. DOI 10.1002/mop.25640

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Completeness Of Cytoreductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*

Yan

Deraco²,

Élias

et al. 2010

Cancer

Self Cite

135

View full text Add to dashboard Cite

show abstract

“…Cytoreductive surgery and HIPEC is now the standard of care of pseudomyxoma peritonei and peritoneal mesothelioma. [31,32] It is considered the standard of care for colorectal peritoneal metastases with a limited peritoneal spread. [33,34] It is also shown benefit for gastric cancer with limited peritoneal spread and has been the only modality that has the potential to prolong survival in this sub group of patients with a very poor prognosis otherwise.…”

Section: Rationale For Hyperthermic Intraperitoneal Chemotherapy (Hipec)mentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

show abstract

“…The most common indications are pseudomyxoma peritonei and appendiceal tumors with PM, peritoneal mesothelioma, colorectal cancer with limited PM, selected patients of gastric cancer with limited PM and recurrent ovarian cancer [2][3][4][5][6]. Trials are underway to evaluate its role in ovarian cancer as first line and second line therapy [6].…”

Section: Introductionmentioning

confidence: 99%

Safety considerations for Health care Workers involved in Cytoreductive Surgery and Perioperative chemotherapy

Bhatt

Mittal

Gopinath³

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

The combined modality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has gained worldwide acceptance for management of selected patients with peritoneal metastases from various cancers. Cytoreductive surgery is performed with the goal of removing all macroscopic disease and is coupled with perioperative chemotherapy (POC) in the form of HIPEC with or without EPIC (early postoperative intraperitoneal chemotherapy) to deal with the microscopic residual disease. These treatments entail the use of cytotoxic drugs in the operation theatre or in the intensive care unit where they are not commonly used and put the healthcare workers participating in the treatment at risk of exposure. CRS is performed with high voltage electrocautery generating a large amount of surgical smoke which is inhaled by the involved personnel and has potential health hazards. This article outlines the safety measures to be taken while performing CRS and POC.

show abstract

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

Abstract: The data suggest that CRS combined with HIPEC achieved prolonged survival in selected patients with DMPM.

Cited by 615 publications

References 29 publications

A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*

A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Safety considerations for Health care Workers involved in Cytoreductive Surgery and Perioperative chemotherapy

Contact Info

Product

Resources

About